



Hemophilia

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	3
2. RECOGNITION AND DIAGNOSIS	5
Medicare Coverage Workup.....	5
Subtle Early Signs in Older Adults (>65)	6
Geriatric Risk Factors	7
Diagnostic Thresholds.....	8
Common Symptoms	9
Common Oversights	10
Key Differentials in Elderly	11
Comorbidity Screening.....	12
Bleeding Severity Classification	13
3. MEAT DOCUMENTATION ESSENTIALS	13
Clinical Documentation Elements	14
Reframing Common Documentation Shortcuts	15
4. TREATMENT AND REFERRAL QUICK GUIDE	16
Therapy Escalation Criteria	16
Hemophilia — Treatment Options	17
Non-Pharmacologic Care and Supportive Interventions	18
Medication Safety and Key Interactions	19
When to Refer	20
Follow-Up Timing	21
Comorbidity Management — Primary Care Role.....	21
Cost-Smart Options	22
Patient Education and Adherence	23
Quality Metrics Tie-In	24
5. CODING REMINDERS AND CASE EXAMPLES	26
Coding Specificity	26
Annual Clinical Review and Confirmation	28
Good Documentation is Comprehensive Coding	28
EHR Workflow Tips	29
Brief Case Examples	29
REFERENCES	30

1 CLINICAL SNAPSHOT

Definition: Hemophilia is a **hereditary X-linked recessive bleeding disorder** caused by deficiency of coagulation factor VIII (Hemophilia A) or factor IX (Hemophilia B); rarer factor XI deficiency is Hemophilia C.¹ Severity is classified by baseline factor activity level: severe (<1%) — spontaneous joint and muscle bleeds; moderate (1-5%) — bleeding after minor trauma; mild (5-40%) — bleeding only after surgery/major trauma.² **Acquired Hemophilia A (AHA) is clinically distinct** — autoimmune inhibitory antibodies against endogenous FVIII, median age at diagnosis around 75 years, incidence 3-4 per million/year in adults ≥60, mortality ≥20% in patients >65.³

ICD-10 Codes:

Hereditary: **D66** (Hemophilia A, FVIII deficiency); **D67** (Hemophilia B, FIX deficiency); **D68.1** (Hemophilia C, FXI deficiency). Acquired: **D68.311** (Acquired Hemophilia A, autoimmune inhibitors) — clinically and codewise distinct from hereditary; **D68.4** (acquired factor deficiency, NOT autoimmune) does not map to HCC. **AVOID: Z14.01** (asymptomatic carrier) and **Z14.02** (symptomatic carrier) carry NO HCC weight — never use as primary for active hemophilia disease. Associated bleeding codes: **M25.0x** (hemarthrosis by joint, ~70-80% of bleeds), **I61.x** (intracranial hemorrhage), **K92.0-K92.2** (GI hemorrhage), **M17.4-M17.5** (hemophilic arthropathy, secondary OA), **B18.2** (chronic HCV — ~80% seroprevalence in pre-1990 cohort), **C22.0** (hepatocellular carcinoma surveillance), **I48.x** (atrial fibrillation), **I25.x** (ischemic heart disease).

Prevalence and Burden: The estimated frequency of hemophilia is around **1 in 10,000 live births**.¹ Hemophilia A affects ~**1 in 5,000** male births (~20,000 US persons); Hemophilia B ~**1 in 30,000** male births (~4,000 US persons);¹ ~30% of all cases arise from de novo mutations with **no family history**.⁴ Inhibitor development is the most costly complication: 30-50% of severe Hemophilia A patients develop FVIII inhibitors; Hemophilia B rate 1.5-3%.^{5,6} Clotting factor concentrates account for ~90% of total direct medical costs in PwH treated at HTC's.⁷

HCC/RAF V28 Mapping

ICD-10 CODE(S)	HCC CATEGORY (V28)	RAF (CNA)	DOCUMENTATION REQUIREMENT
D66 (Hemophilia A, FVIII)	HCC 111 — Hemophilia/Male	4.639	Hereditary etiology confirmed; baseline FVIII activity level (% or IU/mL); inhibitor status (positive/negative, titer in Bethesda Units); current prophylaxis regimen; documented annually in MA (not a carry-forward diagnosis) ⁷
D67 (Hemophilia B, FIX)	HCC 111	4.639	Hereditary etiology; baseline FIX activity level; inhibitor status; note: emicizumab is NOT indicated for Hem B — document correct type to support prescribing ⁷

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time